A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results

@article{Pieri2013AP2,
  title={A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results},
  author={Lisa Pieri and Chiara Paoli and Paola Guglielmelli and Rajmonda Fjerza and Umberto Arena and Fabio Marra and Stefano Colagrande and Fabio Mori and Roberto Marchioli and Raffaella Pioggiarella and Marco Ruggeri and Ilaria Nichele and Guido Finazzi and Maria Luisa Ferrari and Vittorio Rosti and Valerio de Stefano and Elisa Rumi and Carmela Mannarelli and Tiziana Fanelli and Alberto Bosi and Alessandro Rambaldi and Giovanni Barosi and Mario Cazzola and Tiziano Barbui and Alessandro Maria Vannucchi},
  journal={Blood},
  year={2013},
  volume={122},
  pages={1583-1583}
}
Philadelphia-negative Myeloproliferative Neoplasms (MPN) include Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis, both Primary (PMF) and secondary to PV or ET (PPV-MF and PET-MF). A MPN is frequently the underlying cause of splanchnic vein thrombosis (SVT), accounting for 31.5% of portal vein thrombosis (PVT) and 40.9% of Budd Chiari syndrome (BCS). In patients (pts) with MPN and SVT, splenomegaly can arise as the consequence of the hematological disease and/or blood… 
Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
TLDR
Findings from the pivotal phase 3 COMFORT studies showed that ruxolitinib-associated reductions in MF-related splenomegaly and symptom burden occur rapidly and in the majority of patients, and two- and 3-year follow-up data suggest that the benefits of ruxolinib are durable and associated with a survival advantage compared with conventional therapies.
Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors
TLDR
The purpose of this article is to help oncology APs with the knowledge they need in order to educate their MF patients, to help them to remain on therapy, and ultimately, to maximize the overall treatment benefit.